Aquestive Therapeutics will report its Q1 2026 financial results and business highlights on May 13, 2026. The company scheduled a follow-up conference call for May 14 at 8:00 a.m. ET.
The stock closed at $4.13 on May 13, marking a 0.72% decline. Shares rose to $4.65 during after-hours trading amid investor anticipation. Recent closing prices fluctuated between $4.18 and $4.34.
Pre-earnings optimism appears to drive the price uptick despite no major company-specific news. Broader market volatility persists due to ongoing inflationary pressures and geopolitical tensions.